Duopharma Biotech Berhad Income Statement

Financials in millions MYR. Fiscal year is January - December.

Millions MYR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	916.83	931.69	813.7	704.73	696.72	639.18
Revenue Growth (YoY)	3.78%	14.50%	15.46%	1.15%	9.00%	12.16%
Cost of Revenue	549.68	568.56	512.16	436.4	416.9	385.19
Gross Profit	367.15	363.14	301.54	268.33	279.82	253.98
Selling, General & Admin	224.31	226.65	202.02	182.72	186.59	165.78
Other Operating Expenses	2.69	2.17	0.7	2.8	0.81	-0.67
Operating Expenses	227.53	229.36	201.28	189.61	186.91	165.22
Operating Income	139.62	133.78	100.26	78.71	92.91	88.77
Interest Expense	-23.52	-24.16	-25.77	-17.68	-9.1	-6.44
Interest & Investment Income	5.87	5.87	5.97	2.75	1.52	1.2
Other Non Operating Income (Expenses)	-0.4	-0.59	-0.82	-0.52	-0.48	-0.53
EBT Excluding Unusual Items	121.57	114.9	79.63	63.27	84.85	82.99
Gain (Loss) on Sale of Assets	0.01	0.01	0.39	-	-	-0.01
Pretax Income	121.58	114.91	80.02	63.27	84.85	82.98
Income Tax Expense	29.04	27.45	17.38	10.62	14.74	17.3
Net Income	92.54	87.46	62.65	52.65	70.11	65.68
Net Income to Common	92.54	87.46	62.65	52.65	70.11	65.68
Net Income Growth	26.75%	39.62%	19.00%	-24.91%	6.74%	12.07%
Shares Outstanding (Basic)	963	962	962	959	948	928
Shares Outstanding (Diluted)	963	962	962	959	948	928
Shares Change (YoY)	0.08%	-	0.36%	1.08%	2.15%	0.02%
EPS (Basic)	0.10	0.09	0.07	0.05	0.07	0.07
EPS (Diluted)	0.10	0.09	0.07	0.05	0.07	0.07
EPS Growth	26.65%	39.62%	18.57%	-25.71%	4.50%	12.05%
Free Cash Flow	73.87	79.99	59.77	15.86	5.08	-66.16
Free Cash Flow Per Share	0.08	0.08	0.06	0.02	0.01	-0.07
Dividend Per Share	0.045	0.045	0.030	0.023	0.023	0.022
Dividend Growth	51.67%	51.67%	30.44%	-	5.75%	-55.43%
Gross Margin	40.05%	38.98%	37.06%	38.07%	40.16%	39.74%
Operating Margin	15.23%	14.36%	12.32%	11.17%	13.33%	13.89%
Profit Margin	10.09%	9.39%	7.70%	7.47%	10.06%	10.28%
Free Cash Flow Margin	8.06%	8.59%	7.35%	2.25%	0.73%	-10.35%
EBITDA	176.66	171.05	137.34	114.04	122.86	114.94
EBITDA Margin	19.27%	18.36%	16.88%	16.18%	17.63%	17.98%
D&A For EBITDA	37.04	37.27	37.08	35.32	29.95	26.18
EBIT	139.62	133.78	100.26	78.71	92.91	88.77
EBIT Margin	15.23%	14.36%	12.32%	11.17%	13.33%	13.89%
Effective Tax Rate	23.89%	23.89%	21.72%	16.79%	17.37%	20.85%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.